Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Cancer vaccine Stories

2012-06-01 02:22:14

SYOSSET, N.Y., June 1, 2012 /PRNewswire/ -- Dr. Myron Arlen, of Great Neck, New York, has been included in the Strathmore's Who's Who Worldwide Edition for his outstanding contributions and achievements in the field of Biotechnology. About MYRON ARLENDr. Myron Arlen has over 50 years experience in the biotechnology arena. He founded Neogenix Oncology in 2003, a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and...

2012-05-21 23:52:19

Vaccination studies from Mercer University (Ga.) headline the groundbreaking research being unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC). The conference takes place Monday, May 21 - Wednesday, May 23 at the Sheraton San Diego Hotel and Marina. Other topics to be discussed include diversity and complexity of vaccine manufacturing, scale-up and tech transfer strategies, applications of multi-scale systems pharmacology, and...

2012-05-18 01:51:35

Novel adjuvant therapy shows promise for women with a history of breast cancer in Phase II clinical trial A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. The findings, released today, will be presented on...

2012-05-17 06:25:05

WORCESTER, Mass. and TORONTO, May 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine. The following distinguished investigators join Dr. Gabriel N. Hortobagyi, MD, FACP (University of Texas MD Anderson Cancer Center), Dr. Kathy D. Miller, MD (Indiana University School of...

2012-05-15 06:28:55

WORCESTER, Mass. and TORONTO, May 15, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT), in anticipation of the transition into pivotal Phase III trials, is pleased to announce today that the expertise of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., has been expanded by the addition of two globally recognized experts in clinical trial research and immuno-therapeutic treatments of breast cancer: Dr. Kathy D....

2012-05-09 06:26:08

WORCESTER, Mass. and TORONTO, May 9, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that a Scientific Advisory Board (SAB) has been established for its wholly-owned oncology immuno-therapeutics subsidiary, Antigen Express, Inc. The function of the SAB is to provide advice and assistance to Antigen Express in respect of the clinical and regulatory programs for the Company's immuno-therapeutic cancer vaccines. The initial focus of the...

2012-05-08 06:31:02

WORCESTER, Mass. and TORONTO, May 8, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that abstracts featuring the AE37 breast cancer vaccine clinical program of Generex wholly-owned subsidiary Antigen Express, Inc. will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (http://chicago2012.asco.org) taking place June 1-5, 2012 in Chicago, IL. An abstract entitled "From bench to bedside: The use of the li-Key technology...

2012-05-08 02:28:07

NEWARK, Del., May 8, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced issuance of a US patent covering compositions of matter and methods of use of modified lichenase B polypeptides comprising the Company's iBioModulator(TM) platform. The new patent, which provides broad protection of the platform, is US Patent 8,173,408, entitled "Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides." (Logo:...

2012-04-30 22:20:23

BLUE BELL, Pa., May 1, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,168,769, covering Inovio's SynCon® vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV). The patent granted to the Trustees of The University of Pennsylvania has been exclusively licensed to Inovio under its existing license agreement with the university. The patent includes claims...

2012-04-26 02:28:38

NEWARK, Del., April 26, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced further positive results in ongoing tests demonstrating that its proprietary immunomodulator molecule, lichenase (LicKM), enhances the performance of vaccine antigens when produced as fusions to LicKM. iBio indicated it will offer commercial collaborations and product licenses to this novel immunomodulator under the trade name iBioModulator(TM) (Logo:...